[ad_1]
Pfizer will only produce half of the planned doses of vaccines. The reason for this is a problem with the supply chain, Fox News reported.
Large-scale vaccination against Covid-19 has started in Russia
While the vaccine appears to be the only option to help us get back to normal, it will hit hits before we reach a reasonable number of vaccinated. Prevention must be reinforced. https://t.co/6UTWSDMSxg
– Natalia Solenkova, MD PhD (@SolNataMD) December 4, 2020
“It took longer than expected to expand the vaccine supply chain. It is also important to emphasize that the results of clinical trials are delayed longer than originally planned,” said a company spokesman.
COVID-19 and vaccines, what countries provide
Pfizer and its German partner BioNTech had expected to produce 100 million vaccines by the end of the year, but the number of planned doses has now been halved to 50 million.
Pfizer receives raw materials from suppliers in the United States and Europe. Expanding the production of vaccine components last month proved challenging. At the moment, the company is also awaiting the results of the latest tests, says the manufacturer.
Study: Modern vaccine grants immunity for at least three months
The company did not specify which components are missing for production. Vaccines generally contain materials that include antiviral agents, antiseptic fluids, sterile water, and DNA elements from the virus itself that do not cause severe symptoms but activate the immune system to produce antibodies.
Typically, companies first wait for their product approval and only then start acquiring raw materials, setting up production lines, and establishing supply chains.
Kostadin Angelov: the vaccine will be administered only after informed consent
“In this case, it all happened at the same time. We started building supply chains in March, when the vaccine was still in development. This is unprecedented,” said a participant in the vaccine development process at Pfizer.
The UK was the first in the world to approve the Pfizer / BioNTech COVID-19 vaccine
The EU has criticized Britain’s “hasty” approval of the Pfizer-Biontech vaccine
Pfizer / BioNtech currently plans to launch 1.3 billion vaccines in 2021, and the shortage of 50 million doses this year will be offset by increased production.
[ad_2]
